<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02066792</url>
  </required_header>
  <id_info>
    <org_study_id>R34MH099318</org_study_id>
    <nct_id>NCT02066792</nct_id>
  </id_info>
  <brief_title>Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder</brief_title>
  <official_title>Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas at Austin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southern Methodist University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas at Austin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the efficacy of 50 mg of d-cycloserine in comparison
      to placebo (a pill containing no medication) for improving the effectiveness of
      cognitive-behavioral therapy (CBT) in reducing symptoms associated with social anxiety
      disorder. In addition, the study will examine whether the effectiveness of d-cycloserine
      depends on the timing of the pill administration (i.e., 1- hour before the session or
      immediately after the session) as well as the success of the CBT therapy sessions. The
      investigators hypothesize that the tailored post-session DCS administration condition will
      outperform the other conditions (pre-session DCS, placebo, and non-tailored post-session
      DCS). This will be evidenced by short- and long-term improvements in social anxiety severity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Actual">July 1, 2018</completion_date>
  <primary_completion_date type="Actual">July 1, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Social Anxiety Symptom Severity</measure>
    <time_frame>Assessments took place at multiple time points from baseline to 3-month follow-up. The three-month is reported</time_frame>
    <description>The main outcome was a composite Z-score from the Liebowitz Social Anxiety Scale (LSAS) and the Social Phobic Disorders Severity and Change Form (SPD-SC Form).
&quot;The Composite Z-score of the LSAS and SPD-SC Form indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population. Negative numbers indicate values lower symptom severity and positive numbers indicate higher symptom severity.
The LSAS is a 24-item scale that measures fear and avoidance in social and performance situations within the last week, using 0 (no fear/never avoids) to 3 (severe fear/usually avoids) scale. LSAS scores range from 0-144 with higher scores indicated worse outcomes. The SPD-S is the Clinical Global Impression Scale27 adapted for SAD, which instructs evaluators to use a 7-point scale (1=normal, not at all ill; 7=among the most extremely ill patients) to index the severity of social anxiety.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Social Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>Tailored Post-Session DCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs/placebo after the session). The type of pill (i.e. dcs vs. placebo) will be determined after the session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-Session DCS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one dcs before and one placebo after the session).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one placebo after the session).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Tailored Post-Session DCS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs after the session).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-Cycloserine</intervention_name>
    <description>D-cycloserine is a medication thought to be associated with fear extinction.</description>
    <arm_group_label>Non-Tailored Post-Session DCS</arm_group_label>
    <arm_group_label>Pre-Session DCS</arm_group_label>
    <arm_group_label>Tailored Post-Session DCS</arm_group_label>
    <other_name>D-cycloserine, DCS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill</description>
    <arm_group_label>Non-Tailored Post-Session DCS</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Pre-Session DCS</arm_group_label>
    <arm_group_label>Tailored Post-Session DCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Behavioral Therapy</intervention_name>
    <description>This will be a 5-session version of a group CBT protocol with 4-6 patients and 2 therapists per group emphasizing repeated exposure practices. Session 1 involves an introduction and orientation to the CBT model. Sessions 2-5 emphasize repeated exposure tasks, which consist of role-play activities to confront fearful situations in a group setting while disputing cognitive distortions (coupled with the fading of safety behaviors). At the conclusion of each exposure session, patients will be encouraged to continue to apply home-practice strategies (such as giving speeches in front of a mirror). Continued practice of the interventions will be considered part of treatment, and patients will be asked to refrain from alternative treatment for four weeks following completion of the last treatment session.</description>
    <arm_group_label>Non-Tailored Post-Session DCS</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Pre-Session DCS</arm_group_label>
    <arm_group_label>Tailored Post-Session DCS</arm_group_label>
    <other_name>CBT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female outpatients &gt; 18 years of age with a primary psychiatric diagnosis
             (designated by the patient as the most important source of current distress) of social
             anxiety disorder as defined by DSM-5 criteria.

          -  A total score &gt; 60 on the LSAS.

          -  Physical examination and laboratory findings without clinically significant
             abnormalities.

          -  Willingness and ability to participate in the informed consent process and comply with
             the requirements of the study protocol.

        Exclusion Criteria:

          -  A lifetime history of bipolar disorder, schizophrenia, psychosis, delusional disorders
             or obsessive-compulsive disorder; an eating disorder in the past 6 months; organic
             brain syndrome, mental retardation or other cognitive dysfunction that could interfere
             with capacity to engage in therapy; a history of substance or alcohol abuse or
             dependence (other than nicotine) in the last 6 months or otherwise unable to commit to
             refraining from alcohol use during the acute period of study participation.

          -  PTSD within the past 6 months. Entry of patients with other mood or anxiety disorders
             will be permitted if the SAD is judged to be the predominant disorder, in order to
             increase accrual of a clinically relevant sample. Patients with significant suicidal
             ideation (MADRS item 10 score &gt; 3) or who have enacted suicidal behaviors within 6
             months prior to intake will be excluded from study participation and referred for
             appropriate clinical intervention.

          -  Patients must be off concurrent psychotropic medication (e.g., antidepressants,
             anxiolytics, beta blockers) for at least 2 weeks prior to initiation of randomized
             treatment.

          -  Significant personality dysfunction likely to interfere with study participation.

          -  Serious medical illness or instability for which hospitalization may be likely within
             the next year.

          -  Patients with a current or past history of seizures.

          -  Pregnant women, lactating women, and women of childbearing potential who are not using
             medically accepted forms of contraception (e.g., IUD, oral contraceptives, barrier
             devices, condoms and foam, or implanted progesterone rods stabilized for at least 3
             months).

          -  Any concurrent psychotherapy initiated within 3 months of baseline, or ongoing
             psychotherapy of any duration directed specifically toward treatment of the SAD is
             excluded. Prohibited psychotherapy includes CBT or psychodynamic therapy focusing on
             exploring specific, dynamic causes of the phobic symptomatology and providing
             management skills. General supportive therapy initiated &gt; 3 months prior is
             acceptable.

          -  Prior non-response to adequately-delivered exposure (i.e., as defined by the patient's
             report of receiving specific and regular exposure assignments as part of a previous
             treatment).

          -  Patients with a history of head trauma causing loss of consciousness, seizure or
             ongoing cognitive impairment. Current use of isoniazid or ethionamide compounds

          -  Insufficient command of the English language
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Pollack, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Hofmann, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jasper A Smits, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas at Austin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas at Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 17, 2014</study_first_submitted>
  <study_first_submitted_qc>February 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2014</study_first_posted>
  <results_first_submitted>April 8, 2020</results_first_submitted>
  <results_first_submitted_qc>May 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 9, 2020</results_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Social Phobia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Phobia, Social</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cycloserine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT02066792/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tailored Post-Session DCS</title>
          <description>Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs/placebo after the session). Individuals are administered dcs after the session if exposure is determined successful (SUDS below 40). Individuals are administered the placebo is exposure is determined unsuccessful.
The type of pill (i.e. dcs vs. placebo) administered after session is determined after the session.
D-Cycloserine: D-cycloserine is a medication thought to be associated with fear extinction.
Placebo: Sugar pill</description>
        </group>
        <group group_id="P2">
          <title>Pre-Session DCS</title>
          <description>Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one dcs before and one placebo after the session).
D-Cycloserine: D-cycloserine is a medication thought to be associated with fear extinction.
Placebo: Sugar pill</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one placebo after the session).
Placebo: Sugar pill</description>
        </group>
        <group group_id="P4">
          <title>Non-Tailored Post-Session DCS</title>
          <description>Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs after the session).
D-Cycloserine: D-cycloserine is a medication thought to be associated with fear extinction.
Placebo: Sugar pill</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tailored Post-Session DCS</title>
          <description>Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs/placebo after the session). DCS will be administered if the session is deemed a success.
D-Cycloserine: D-cycloserine is a medication thought to be associated with fear extinction.
Placebo: Sugar pill</description>
        </group>
        <group group_id="B2">
          <title>Pre-Session DCS</title>
          <description>Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one dcs before and one placebo after the session).
D-Cycloserine: D-cycloserine is a medication thought to be associated with fear extinction.
Placebo: Sugar pill</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one placebo after the session).
Placebo: Sugar pill</description>
        </group>
        <group group_id="B4">
          <title>Non-Tailored Post-Session DCS</title>
          <description>Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs after the session).
D-Cycloserine: D-cycloserine is a medication thought to be associated with fear extinction.
Placebo: Sugar pill</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="38"/>
            <count group_id="B4" value="36"/>
            <count group_id="B5" value="152"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="152"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.78" spread="9.88"/>
                    <measurement group_id="B2" value="29.73" spread="10.42"/>
                    <measurement group_id="B3" value="28.76" spread="11.81"/>
                    <measurement group_id="B4" value="27.54" spread="8.29"/>
                    <measurement group_id="B5" value="29.20" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Social Anxiety Symptom Severity</title>
        <description>The main outcome was a composite Z-score from the Liebowitz Social Anxiety Scale (LSAS) and the Social Phobic Disorders Severity and Change Form (SPD-SC Form).
&quot;The Composite Z-score of the LSAS and SPD-SC Form indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population. Negative numbers indicate values lower symptom severity and positive numbers indicate higher symptom severity.
The LSAS is a 24-item scale that measures fear and avoidance in social and performance situations within the last week, using 0 (no fear/never avoids) to 3 (severe fear/usually avoids) scale. LSAS scores range from 0-144 with higher scores indicated worse outcomes. The SPD-S is the Clinical Global Impression Scale27 adapted for SAD, which instructs evaluators to use a 7-point scale (1=normal, not at all ill; 7=among the most extremely ill patients) to index the severity of social anxiety.</description>
        <time_frame>Assessments took place at multiple time points from baseline to 3-month follow-up. The three-month is reported</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Tailored Post-Session DCS</title>
            <description>Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs/placebo after the session). Individuals are administered dcs after the session if exposure is determined successful (SUDS below 40). Individuals are administered the placebo is exposure is determined unsuccessful.
The type of pill (i.e. dcs vs. placebo) administered after session is determined after the session.
D-Cycloserine: D-cycloserine is a medication thought to be associated with fear extinction.
Placebo: Sugar pill</description>
          </group>
          <group group_id="O2">
            <title>Pre-Session DCS</title>
            <description>Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one dcs before and one placebo after the session).
D-Cycloserine: D-cycloserine is a medication thought to be associated with fear extinction.
Placebo: Sugar pill</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one placebo after the session).
Placebo: Sugar pill</description>
          </group>
          <group group_id="O4">
            <title>Non-Tailored Post-Session DCS</title>
            <description>Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs after the session).
D-Cycloserine: D-cycloserine is a medication thought to be associated with fear extinction.
Placebo: Sugar pill</description>
          </group>
        </group_list>
        <measure>
          <title>Social Anxiety Symptom Severity</title>
          <description>The main outcome was a composite Z-score from the Liebowitz Social Anxiety Scale (LSAS) and the Social Phobic Disorders Severity and Change Form (SPD-SC Form).
&quot;The Composite Z-score of the LSAS and SPD-SC Form indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population. Negative numbers indicate values lower symptom severity and positive numbers indicate higher symptom severity.
The LSAS is a 24-item scale that measures fear and avoidance in social and performance situations within the last week, using 0 (no fear/never avoids) to 3 (severe fear/usually avoids) scale. LSAS scores range from 0-144 with higher scores indicated worse outcomes. The SPD-S is the Clinical Global Impression Scale27 adapted for SAD, which instructs evaluators to use a 7-point scale (1=normal, not at all ill; 7=among the most extremely ill patients) to index the severity of social anxiety.</description>
          <population>Intent-to-treat</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.46" spread=".13"/>
                    <measurement group_id="O2" value="-.90" spread=".13"/>
                    <measurement group_id="O3" value="-.39" spread=".14"/>
                    <measurement group_id="O4" value="-.88" spread=".14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At 3 month follow-up</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>two-sided</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Four level multivariate MLM with measures nested within time, which was nested within subjects, who were nested within treatment cohort.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-.81</ci_lower_limit>
            <ci_upper_limit>-.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3 month follow-up</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.635</p_value>
            <p_value_desc>Two-sided</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Four level multivariate MLM with measures nested within time, which was nested within subjects, who were nested within treatment cohort.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-.37</ci_lower_limit>
            <ci_upper_limit>.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Four level multivariate MLM with measures nested within time, which was nested within subjects, who were nested within treatment cohort.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-.80</ci_lower_limit>
            <ci_upper_limit>-.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>3 month follow-up</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.004</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Four level multivariate MLM with measures nested within time, which was nested within subjects, who were nested within treatment cohort.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-.73</ci_lower_limit>
            <ci_upper_limit>-.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3 month follow-up</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.008</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Four level multivariate MLM with measures nested within time, which was nested within subjects, who were nested within treatment cohort.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-.72</ci_lower_limit>
            <ci_upper_limit>-.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data for adverse events was collected at each assessment point over the course of the study (e.g., in-person screening, baseline appointment, sessions 1-5, and the 1-week, 1-month, and 3-month follow-ups).</time_frame>
      <desc>Participants were asked if they had experienced any injuries or illnesses at the beginning of each study visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tailored Post-Session DCS</title>
          <description>Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs/placebo after the session). DCS will be administered if the session is deemed a success.
D-Cycloserine: D-cycloserine is a medication thought to be associated with fear extinction.
Placebo: Sugar pill</description>
        </group>
        <group group_id="E2">
          <title>Pre-Session DCS</title>
          <description>Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one dcs before and one placebo after the session).
D-Cycloserine: D-cycloserine is a medication thought to be associated with fear extinction.
Placebo: Sugar pill</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one placebo after the session).
Placebo: Sugar pill</description>
        </group>
        <group group_id="E4">
          <title>Non-Tailored Post-Session DCS</title>
          <description>Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs after the session).
D-Cycloserine: D-cycloserine is a medication thought to be associated with fear extinction.
Placebo: Sugar pill</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Serious Adverse Event</sub_title>
                <description>Participant was hospitalized for an aborted suicide attempt during the follow-up phase of the study.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jasper Smits</name_or_title>
      <organization>Institute for Mental Health Research and Department of Psychology, The University of Texas at Austin</organization>
      <phone>512-475-8095</phone>
      <email>smits@utexas.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

